IP Library Patent Application 17631006
Patent Application
App. No. 17/631,006

UNIVERSAL CAR-T CELL AND PREPARATION AND USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/631,006
Abstract

Provided is a non-naturally occurring T population, of which the proportion of T memory stem cells satisfies C1≥50%. The T cell population comprises a tumor antigen-targeting universal CAR-T cell. Further provided is a method for preparing the CAR-T cell. The CAR-T cell is higher in amplification rate and better in phenotype, IFN-gamma releasing capacity and target cell killing capability.

Claims (16)

1 . A non-naturally occurring T cell population, characterized in that a proportion C1 of T memory stem cells (Tscm) in the T cell population is 50%, based on the total number of T cells in the T cell population.

2 . The T cell population as described in claim 1 , characterized in that the T memory stem cells comprise CAR-T cells.

3 . The T cell population as described in claim 1 , characterized in that the T memory stem cells comprise CCR 7+ CD45RA + T cells.

4 . The T cell population as described in claim 1 , characterized in that, in the T cell population, a proportion C2 of those expressing a biomarker CCR7 is 50%, preferably 60%, more preferably, 70%.

5 . The T cell population as described in claim 1 , characterized in that the CAR-T cells are universal CAR-T cells targeting tumor antigens.

6 . A cell preparation, characterized in that, the cell preparation contains the non-naturally occurring T cell population described in claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

7 . A method for preparing CAR-T cells, characterized in that, comprising steps of:

(a) providing an isolated T cell;

(b) amplifying and culturing the isolated T cells in the presence of IL15, IL7 and IL21, thereby obtaining cultured T cells; and

(c) transforming the cultured T cells to prepare CAR-T cells.

8 . The method as described in claim 1 , characterized in that, in step (a), the isolated T cells are selected from a group of: naive T cells (Tn cells), a Tn cell-enriched cell population, or total T cells, or a combination thereof.

9 . The method as described in claim 1 , characterized in that, in step (b), when the isolated T cells are amplified and cultured, the concentration of IL15 in the culture system is 1-200 ng/ml, preferably 3-100 ng/ml, more preferably 5-20 ng/ml; the concentration of IL7 is 0.5-50 ng/ml, preferably, 1-20 ng/ml, more preferably 3-10 ng/ml; and the concentration of IL21 is 1-100 ng/ml, preferably, 3-50 ng/ml, more preferably 5-20 ng/ml.

10 . A method for preparing CAR-T cells, comprising steps of:

(i) providing an isolated Tn cell,

(ii) optionally, amplifying and culturing the isolated T cells in the presence of IL15, IL7 and IL21 to obtain cultured T cells; and

(iii) transforming the T cells to prepare CAR-T cells.

Assignments (5)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062153/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: JI, YUN; YANG, WEI-CHIH; CUI, HUIJUAN; LUO, XIAOBING; HUANG, JIAQI; ZHU, SHIGUI; YAO, XIN; YAO, YIHONG
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.; WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 059733/0879 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 059733/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: WUXI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 059739/0592 →